Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 11/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 4/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL70914 | 0.98 | HTR2C (0.38) | SLC6A2SLC6A4IRAK4SLC18A3SIGMAR1 | |
| SCHEMBL1238976 | 0.84 | CYP1A2 (0.41) | HTR2CHTR2AHTR2BHRH3 | |
| Methylamine SCHEMBL28000602 | 0.79 | CYP3A4 (0.42) | SLC6A2SLC6A4SIGMAR1SLC6A3 | |
| SCHEMBL83792 | 0.79 | SLC6A4 (0.47) | SLC6A2SLC6A4IRAK4SLC18A3SIGMAR1 | |
| SCHEMBL13708519 | 0.78 | HTR2A (0.45) | HTR2CHTR2A | |
| Hydrochloric Acid SCHEMBL70661 | 0.78 | SLC6A4 (0.46) | SLC6A2SLC6A4IRAK4HTR2CSLC6A3 | |
| Methylamine SCHEMBL28000436 | 0.78 | CYP3A4 (0.41) | SLC6A2SLC6A4SIGMAR1HTR2CSLC6A3 | |
| SCHEMBL1006288 | 0.77 | SIGMAR1 (0.45) | SLC6A2SLC6A4IRAK4SIGMAR1SLC6A3 | |
| SCHEMBL83005 | 0.77 | HTR2C (0.53) | SLC6A2SLC6A4HTR2CSLC6A3 | |
| SCHEMBL91490 | 0.77 | NOS3 (0.34) | HTR2CHTR2AHTR2BHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129376-B2 | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-03-06 | — | — | US | disclosed |
| US-8129376-B2 | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-03-06 | — | — | US | disclosed |
| CN-102036558-A | Novel piperidine derivatives as stearoyl-CoA desaturase inhibitors | FOREST LAB HOLDINGS LTD | 2011-04-27 | — | — | CN | disclosed |
| EP-2268143-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | Forest Laboratories Holdings Limited (BM) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009117676-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | WO | disclosed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | SLC6A2 4356/4885SLC6A4 4287/4885IRAK4 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.